{
  "name" : "_cyber.sci-hub.se_MTAuMTAxNi9qLnlydHBoLjIwMTYuMTIuMDA4_mattsson2016.pdf",
  "metadata" : {
    "source" : "META",
    "title" : "The changing face of nanomaterials: Risk assessment challenges along the value chain",
    "authors" : [ "Mats-Olof Mattsson", "Myrtill Simkó" ],
    "emails" : [ "mats-olof.mattsson@ait.ac.at" ],
    "sections" : [ {
      "heading" : null,
      "text" : "Accepted Manuscript\nThe changing face of nanomaterials: Risk assessment challenges along the value chain Mats-Olof Mattsson, Myrtill Simkó\nPII: S0273-2300(16)30388-9 DOI: 10.1016/j.yrtph.2016.12.008 Reference: YRTPH 3743\nTo appear in: Regulatory Toxicology and Pharmacology\nReceived Date: 19 August 2016 Revised Date: 17 November 2016 Accepted Date: 15 December 2016\nPlease cite this article as: Mattsson, M.-O., Simkó, M., The changing face of nanomaterials: Risk assessment challenges along the value chain, Regulatory Toxicology and Pharmacology (2017), doi: 10.1016/j.yrtph.2016.12.008.\nThis is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n1\n2\nThe changing face of nanomaterials: risk 3\nassessment challenges along the value chain 4\nMats-Olof Mattsson1,2* and Myrtill Simkó1,2 5\n1. AIT Austrian Institute of Technology, Energy Department, Environmental 6\nResources and Technologies, Konrad-Lorenz-Strasse 24, 3430 Tulln, 7\nAustria 8\n2. SciProof International AB, Vaktpoststigen 4, 83132 Östersund, Sweden 9\n*Corresponding author. 10\ne-mail address: mats-olof.mattsson@ait.ac.at 11\nphone: +43 50550 3425; fax: +43 50550 3452 12\nabstract word count: 119 13\nmain text word count: 7306 14\nreferences word count: 1844 15\n16\n17\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nABSTRACT 18\nRisk assessment (RA) of manufactured nanomaterials (MNM) is essential for regulatory purposes and 19 risk management activities. Similar to RA of “classical” chemicals, MNM RA requires knowledge 20 about exposure as well as of hazard potential and dose response relationships. What makes MNM RA 21 especially challenging is the multitude of materials (which is expected to increase substantially in the 22 future), the complexity of MNM value chains and life cycles, the accompanying possible changes in 23 material properties over time and in contact with various environmental and organismal milieus, and 24 the difficulties to obtain proper exposure data and to consider the proper dose metric. This article 25 discusses these challenges and also critically overviews the current state of the art regarding MNM 26 RA approaches. 27\n28 Keywords: nanomaterials; risk assessment approach; risk management; value chain; life cycle; 29 grouping; dose metric 30 31\n32\nM AN\nUS CR\nIP T\nAC CE\nPT ED"
    }, {
      "heading" : "1 Introduction 33",
      "text" : "Technologies and materials that operate and/or function at the nanometre scale (manufactured 34 nanomaterials, MNM) have been forecasted to significantly influence several sectors of the economy 35 and the society. In parallel, the consciousness about safety aspects for the successful implementation 36 of nanotechnologies and MNM has manifested itself in several ways, including substantial public 37 funding for scientific research regarding nanosafety. The obvious driver behind the focus on risk and 38 safety is the fact that these technologies and materials possibly behave differently than the same 39 materials when they are existing as chemicals in solution, or as particles of larger sizes (i.e. above 40 several hundreds of nm). The term “nanotoxicology” has been used to characterize toxicological 41 studies intended to find out potential environmental, health and safety (EHS) effects of MNM. Such 42 studies have been underpinned by an assumption that materials engineered to utilize unique 43 properties associated with the nanoscale must exhibit nanoscale-specific toxicology. This assumption 44 is not uncontested. However, research shows that toxicity of many nanomaterials is possible, and to 45 some extent predictable from non-nanoscale materials (e.g. (McShan et al., 2014; Oberdorster et al., 46 2005; Xia et al., 2009). 47\nDespite a considerable amount of scientific studies during the last decade (for a recent overview of 48 development of nanomaterial-related risk assessment, see (Schulte et al., 2016)), question marks 49 remain regarding the fate and behaviour of MNM in various settings, and whether or not these 50 materials have any (detrimental) effect on human health or the environment. Complicating matters 51 for safety evaluation, and thus also for regulatory purposes, is the fact that there is not one single 52 definition of nanomaterials. In contrast, definitions have been suggested by many different actors, 53 such as the European Commission, various governmental organisations, industrial representatives 54 and standards organisations (see (Boverhof et al., 2015) for a recent overview). 55\nFor regulatory purposes and for risk management activities, a proper risk assessment (RA) of MNM 56 for human health and the environment is essential (cf. (Hristozov et al., 2014; Savolainen et al., 57\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n2010). Importantly, the RA must in such cases transcend being primarily toxicity screens and tools for 58 identification of research needs. 59\nAmong several key areas of knowledge that are needed for RA, the information about whether or not 60 an exposure to MNM occurs is central, as well as knowledge about the physical-chemical properties 61 of the material, and how these can influence the interaction with biological systems. 62\nThe RA task is made even more complex by two time-related scenarios, viz.: 63\n- that MNMs exist along a value chain - which encompasses MNM manufacture, product 64 production, use and consumption, and end of life - and thus have their own (external) life 65 cycles, and 66\n- that MNMs can possibly enter and subsequently undergo changes within an organism, as 67 well as being affected by the environment and the different media (matrices) that the 68 material is encountering. 69\nThe possibility for interactions with biological processes may vary considerably along these two axes. 70\nThe purpose of the present article is to present an overview of the current status regarding 71 manufactured nanomaterials RA as well as the needs and challenges for such activities. At this stage 72 it has to be pointed out that we consider MNM only, thus other (anthropogenic or naturally 73 occurring) nanomaterials are not covered in this paper. Until presently, MNM RA has been 74 performed on a case-by-case basis, which also was recommended by the European Commission´s 75 Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR, 2009b; SCENIHR, 76 2009c). However, due to increasing complexity and number of MNM, this approach can be 77 considered too time-consuming, cumbersome and costly, and would preferentially be replaced by 78 approaches that can deal with multiple materials simultaneously. 79\nWe also discuss to what extent present and suggested approaches are relevant and sufficient taking 80 into account available tools for exposure and hazard assessments, future materials, as well as 81\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nsensitive populations and environments. Our conclusion in the short term is that RA of MNM will 82 remain difficult and often performed on a case-by-case basis, although ambitions are to increasingly 83 use grouping approaches, read-across and computational approaches such as Quantitative Structure 84 Activity Relationship models (QSARs; (Benfenati et al., 2013), which all can digest large amounts of 85 data. Furthermore, we also stress that a meaningful RA of a specific MNM needs to take the value 86 chain along which the material is existing into account. This is important since the form which the 87 original MNM takes during the life of a product may very well change and render the material novel 88 characteristics (“changing the face” of the MNM). These challenges have many similarities with the 89 RA, which is performed regarding conventional chemicals, but we also point to that certain aspects 90 are specifically pertaining to MNM. 91\nRegarding regulation, which is not a subject of this paper, in the European Union, risks of chemicals 92 are regulated by REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals). 93 However there is no nano-specific regulation framework existing. There are nevertheless attempts 94 made to specify nanomaterial specific requirements within REACH, since MNM are covered under 95 the definition of “substance” (ECHA), (see e.g. (Schwirn et al., 2014)). 96\n97"
    }, {
      "heading" : "2 Risk assessment 98",
      "text" : "Risk in the context of human and environmental toxicology is a function of hazard and exposure 99\n(from IUPAC, see (Lewalle, 1999)). 100\nRegarding risk assessment, a generally agreed upon definition is not available, but within the 101 community where risk assessment for human health and the environment is performed and 102 observed, it is seen as “a process by which scientists evaluate the potential for adverse health or 103 environmental effects from exposure to naturally occurring or synthetic agents” (Society of 104 Toxicology, 1998). The goal is to provide risk managers (authorities, health and safety personnel etc.) 105\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nwith a science-based foundation for decision-making in management of agents possibly affecting 106 health and environment. 107\nThe principal stages of risk assessment are (Figure 1): 108\n- Hazard identification 109\n- Examination of dose-response relationships (hazard characterization) 110\n- Exposure assessment 111\n- To highlight uncertainties in the determination of hazards and dose-response relationships 112\nA health risk assessment typically evaluates the evidence within several areas of studies (such as 113 human, animal, cellular, modelling and in silico studies). Obtaining data from different types of 114 studies make it thus possible to integrate the various pieces of data, to perform an integrative risk 115 assessment. Main characteristics of the different types of studies are provided below. 116\nHuman (epidemiology) studies investigate the occurrence and distribution of diseases in populations 117 to learn about the causes of disease, which may lead to preventive measures. Human studies are 118 usually observational and therefore vulnerable to bias and confounding 119\nIn vivo (animal) studies provide information about effects on a whole living organism displaying the 120 full repertoire of body structures and functions, such as nervous system, endocrine systems, and 121 immune responses. There are extrapolation problems with inter- and intraspecific variations. 122 However in vivo studies are powerful for health risks assessment especially if they confirm 123 epidemiologic findings. 124\nIn vitro assays investigate toxicological, mechanistic and other relevant effects by providing evidence 125 for and possible understanding of the development of diseases using a wide variety of biological 126 endpoints. In vitro assays can be used for hazard identification, however their usefulness for risk 127 assessment is limited. (SCENIHR, 2009a) 128\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nThe scientific literature contains a vast number of studies that can be used as part of MNM RA. These 129 studies deal with issues ranging from exposure assessment, physical-chemical characterization of 130 materials, mode of action, to specific disease outcomes in experimental settings, etc. However, there 131 are not that many epidemiological studies that specifically address the correlations between MNM 132 exposure and disease outcomes. What is available is a number of studies that have focused on air 133 pollution and particulate matter, including ultrafine particles (UFP; diameter <100 nm). A large part 134 of present day urban air pollution emanates from UFP, which dominate particle number 135 concentration and also surface area of air pollutants (Delfino et al., 2005; Simkhovich et al., 2008). 136 2008). Regarding specific diseases, epidemiological studies have indicated a role for UFP in 137 respiratory diseases (Frampton, 2007; Kumar et al., 2013), cardiovascular disease (Delfino et al., 138 2005; Simkhovich et al., 2008), and also certain neurological diseases and conditions (Costa et al., 139 2014; Guxens and Sunyer, 2012). A difficulty regarding conclusions from available epidemiological 140 studies is however the insufficient exposure assessments (Schwarze et al., 2006). 141\nIn a recent publication (Liou et al., 2015) reviewed 15 studies, (11 cross-sectional, 4 longitudinal, 1 142 which is a combination of these two categories, and 1 which is a descriptive pilot study) and found 143 relationships between various biomarkers and MNM exposures. The authors discussed that the few 144 longitudinal studies are much stronger in design, however all studies suffered from limited exposure 145 assessment and sample size. 146\n3 Value chains and life cycles 147\n3.1 Value chains 148\nInitially the concept of a value chain (VC) was described as a chain of activities that a firm operating 149 in a specific industry performs in order to deliver a valuable product or service for the market (Porter, 150 1985). In the field of economics, a value chain is understood as a structure that can be used to 151 categorize and organize factors related to industrial organization; the activities, places and firms 152\nM AN\nUS CR\nIP T\nAC CE\nPT ED\ninvolved in making a product or service. It includes the full range of activities that companies and 153 workers do to bring a product or service from its conception to its end use and beyond. This includes 154 the activities related to producing and transporting the product (supply chain) as well as other value-155 adding activities such as research, design, marketing, and support services (Figure. 2). Thus this can 156 be described as: 157\n- The full range of value-adding activities/business functions: R&D, design, production, 158 logistics, marketing, services 159 - Supply chain/product life cycle stages: inputs, components, final products, distribution/sales, 160 disposal/recycling. 161\nThis description of a complete value chain is both generic as well as perfectly appropriate when 162 describing a value chain that includes the production and further use of products that contain 163 manufactured nanomaterials. 164\nA natural conclusion from inspecting Figure 2 is that the depicted activities and processes can have a 165 large spatial as well as temporal spread. Because of the large scope of a value chain, there are many 166 different players that can have an interest at least in part of the value chain (Table 1). Safety aspects 167 pertain to virtually all included steps, possibly to a lesser extent in steps that are upstream of market 168 introduction. 169\nSafety analyses and RA of MNM that are based on the value chain perspective are not yet available In 170 the scientific literature. There are however both past and on-going research projects that address the 171 value chains, or at least parts thereof, of specific NM-containing products (see (NanoSafetyCluster)). 172\n3.2 Life Cycles and Life Cycle Assessment 173\nISO defines the 'life cycle' of a product system as the consecutive and interlinked stages of a product 174 system, from raw material acquisition or generation from natural resources to final disposal (i.e. 175 cradle-to-grave) ((ISO/14040, 2006; ISO/14044, 2006); Figure 3)). Life Cycle Analysis (LCA) is a 176\nM AN\nUS CR\nIP T\nAC CE\nPT ED\ncomprehensive framework that quantifies ecological and human health impact of a product or 177 system over its complete life cycle (Hischier and Walser, 2012). This concept is generally accepted 178 and has been the subject for a substantial number of studies. There are even internationally 179 accepted Application guidelines for how to perform such analyses (ISO/14040, 2006; ISO/14044, 180 2006). Current developments in LCA were recently overviewed by (Finnveden et al., 2009). 181\nThe life cycle differs from the value chain in at least two aspects. The value chain provides more of a 182 helicopter perspective for the specific product, including the fundamental research, which is behind 183 the material/product. The focus is thus on the activities, rather than on the physical product. The life 184 cycle of a product/material is on the other hand specific and has a limited duration. At the end of the 185 life cycle, the object comes to an end and exists no more, although the components may be recycled. 186\nOnly a few studies have applied LCA to nanotechnologies and MNM. Lazarevic and Finnveden 187 identified 25 such studies (Lazarevic and Finnveden, 2013). These only looked at part of the life cycle, 188 with no quantitative studies addressing the impact of NMs to health and the environment. 189\nFor MNM RA purposes, it is of vital importance that the material´s life cycle is comprehensively 190 mapped. As can be seen from Figure 3, the life cycle contains several stages, which each very likely 191 keep the MNM in a stage specific form, or appearance. Measurements of the released amounts, as 192 well as description of the forms are necessary for each of these steps. It is very likely that the MNM 193 in question is different in many respects between the different life cycle stages, and thus needing 194 separate RA. 195\nThe release of MNM, irrespective of its form, can possibly occur during production of the MNM 196 containing product. Such a release is likely of primary concern for the worker, although 197 environmental exposure cannot be excluded per se. The consumer can possibly experience exposure 198 during use and maintenance of the product. A major part of the release to the environment is 199 expected to occur at the end of life, where recycling, reuse of material, and various disposal activities 200 are taking place. Occupational exposure can possibly also take place in connection with these 201\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nprocesses. However, it is a challenge to determine if the primary MNM will still be present at the end 202 of life or if it has changed into a novel composite material, dissolved into the bulk material(s), or if 203 there are non-nanomaterials undergoing a transient phase of nanomaterial-like structure. Even 204 though that the latter form is not a MNM it can be still present also as e.g. background exposure. 205 Furthermore, MNM properties can also dramatically change if they are part of a composite material, 206 making the analysis even more difficult. The same complexity regarding possible changes in material 207 characteristics is of course also valid for consumers, although consumer exposure would not be 208 expected along the entire value chain. 209\n4 MNM risk assessment – approaches and results 210\nThe scientific literature contains a significant number of studies that have at least some relevance for 211 risk assessment of MNM, particularly in the form of hazard identification studies. However, there are 212 very few articles that actually perform a proper and complete RA for a given MNM, taking exposure, 213 hazard identification and dose-response relationship studies, as well as uncertainty analysis into 214 consideration. The following section provides examples of suggested approaches to MNM RA and 215 also highlights a few studies that have been identified as MNM risk assessments. 216\n4.1 MNM RA approaches 217\nA number of authors have recently published articles that suggest approaches to risk assessment of 218 MNM. These documents often display more or less formal guidelines to the RA approach, suggesting 219 certain practical methods. A recent comprehensive summary was published by Hristozov and co-220 authors (Hristozov et al., 2016), who collected available frameworks and tools from the published 221 scientific literature, from so-called “grey” literature, and from surveys. They evaluated the 222 frameworks according to six criteria, and also analysed the usefulness of the tools that are used in 223 the different frameworks. Their conclusion was that the identified frameworks were based on the RA 224 framework for chemicals. The authors further recommend a number of adaptations to address the 225\nM AN\nUS CR\nIP T\nAC CE\nPT ED\ncomplexities associated with MNM. None of the frameworks fulfilled all the quality criteria. 226 Regarding the different tools, it was found that many has been developed, but that their usefulness 227 is seldom known, due to that a proper validation is difficult because of lack of appropriate data. 228\nRegarding specific published studies on MNM RA, several recent papers provide useful information 229 regarding specific protocols that have been developed. Thus, Bos et al (Bos et al., 2015) presented 230 the approach suggested by the EU FP7 project MARINA (www.marina-fp7.eu), which includes a two-231 step protocol where the first one focuses on framing of the problem and identification of relevant 232 exposure scenarios. The risk assessment itself is performed in the second stage, where risk 233 characterisation, identification of data needs, collection and analysis of data are performed in an 234 iterative fashion until it is possible to conclude on the possible risks in the specific relevant exposure 235 scenario (RES). The study does not present any concrete applications of the developed approach. 236\nDekkers et al (Dekkers et al., 2016) recently proposed a RA approach developed within the EU FP7 237 NANoREG project (www.nanoreg.eu) that relies on evaluation of specific key features of exposure, 238 kinetics, and hazards (“elements”). These determinants of toxicity include exposure potential, 239 dissolution, transformation, accumulation, genotoxicity, and immunotoxicity. The authors 240 furthermore suggest that their “flow chart” approach allows identification of instances where it is 241 appropriate to use grouping, read-across and QSAR tools in the assessment. The approach distances 242 itself from a case-by-case approach to RA, but it is difficult to see how that can be obtained without a 243 specific investigation of the details of a given MNM. There are furthermore no real examples of QSAR 244 use in the article. The approach is probably not easily adoptable by regulators in need of a RA at this 245 stage due to the need for substantial amounts of benchmark data. The authors furthermore 246 recognize that specific case studies are needed to test and refine the approach. 247\nA different approach is advocated by Hendren et al (Hendren et al., 2015) who suggest an approach 248 to MNM RA based on functional assays rather than starting with physical-chemical properties. The 249 functional assays are suggested to be used to measure MNM behaviour in systems. The study 250\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nprovides two conceptual demonstrations of scenarios forecasting risk for the soil inhabiting 251 nematode C. elegans subjected to Ag nanoparticle exposures. The examples show that the same 252 material (PVP-coated Ag particles, 45 nm diameter) can be differently “risky” for the nematodes, 253 based on functional assays for surface affinity and dissolution rate of the material, due to different 254 environments. 255\nOomen et al (Oomen et al., 2014) reporting on a NanoSafety Cluster Working Group approach, 256 suggested a tiered approach that starts with realistic exposure scenarios (RES). In the presence of a 257 RES, the next step involves characterization of physical-chemical properties, QSAR determinations 258 and evaluation of existing data. The following step comprises a limited set of in vitro and in vivo tests 259 to determine if further testing is needed. A clear advantage with the approach is that after each tier, 260 the available information is used to decide whether or not it is possible to waive further testing. 261\nSharma et al (Sharma et al., 2016) published their multistage framework approach to testing and 262 stressed exposure relevance, MNM transformation, and relevant dose metrics. The framework 263 progresses in stages: 264\n- development of exposure scenarios, 265 - identification and characterization of MNM forms relevant to real-world exposure scenarios 266 and routes, 267 - performing in vitro testing taking MNM transformations, exposure condition, magnitude of 268 exposure (dose), and choice of relevant model systems 269\nA key question regarding MNM transformations is which dose and dose metric that is most relevant. 270 The authors suggest that multiple dose metrics (mass, surface area, particle number) need to be 271 considered. 272\nToxicological studies have typically been performed by means of low-throughput single end-point –273 oriented approaches. This has provided data useful for hazard identification of classical chemicals. It 274 is, however, likely that this type of approach is insufficient for the multitude of NMs, that are present 275\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nand that will arrive in the future. Accordingly, advances made in the field of “omics” technologies and 276 approaches are increasingly being used for computational modelling of effects of MNM (see e.g. 277 (Cohen et al., 2013; Costa and Fadeel, 2016). 278\nA different approach was presented by (Kuempel et al., 2012a) where hazard and risk based grouping 279 of MNM was proposed using a comparative potency analysis of poorly soluble respirable particles 280 (PSP) and a soluble particle that is associated with lung cancer in rats. The authors choose this 281 approach since the PSP provides a possible mode of action (MOA) category for a comparative 282 analysis. However this method suffers from shortcomings as well, since there are data gaps for 283 exposure, MOA of MNM, and uncertainties of RA. 284\nHristozov et al (Hristozov et al., 2016) pointed to the uncertainties of MNM RA for human health and 285 the environment. The authors illuminate that still no full framework exist that fulfil all evaluation 286 criteria for MNM RA but that the development to more quantitative, higher-tier models by 287 incorporating uncertainties are a promising way. 288\nIn summary, a number of RA approaches for MNM have been or are under development. However, 289 the approaches have not been tested and validated at this stage, so their appropriateness remains to 290 be determined. 291\n4.1.1 Grouping approaches 292\nA number of recent articles propose approaches for grouping and testing of MNM, often with a 293 tiered approach to the grouping. Thus Arts et al (Arts et al., 2015) have suggested a strategy which 294 begins with assignment of the MNM in question to main groups of materials based on the basic 295 characteristics of the material, including its chemical composition, morphology, and solubility in 296 water. The second tier takes functional characteristics (dissolution rate, surface reactivity, 297 dispersibility) into account. The third tier investigates specific biological endpoints in short-term 298 animal studies. According to Braakhuis et al (Braakhuis et al., 2016), it is not enough to group MNM 299 based on their intrinsic characteristics if the aim is to predict risks occurring after inhalation. It is also 300\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nnecessary to know kinetic behaviour and how the NM behaves/look like in situ. This includes 301 uptake/adsorption/deposition, distribution, corona formation, and elimination. Also considerations 302 of modes of action and the life cycle of the material in question need to be included. 303\nA predictive model for MNM RA has been proposed by Clark et al (Clark et al., 2011). The aim is to 304 have models that predict which “groups” of MNM, based on their physical-chemical properties that 305 have potentially hazardous properties. This requires large amounts of high quality data. 306\nGoodwin and co-authors (Godwin et al., 2015) have developed a tiered decision-tree approach for RA 307 of MNM that was illustrated by performing RA on CNTs (carbon nanotubes) in the context of the US 308 EPA New Chemicals program. The authors stressed that categorization of MNM for regulatory 309 purposes need to both consider hazard and exposure potential, and furthermore that the use of 310 alternative testing strategies (ATS), when appropriate, complement traditional in vivo testing and can 311 sometimes decrease the use of the latter and make RA less time-consuming. 312\nOomen et al (Oomen et al., 2015) presented a comprehensive view on how grouping and read-across 313 approaches can be applied to MNM RA, developed with in the MARINA project. The idea is that 314 MNMs can be grouped based on limited variation in the materials physical-chemical properties. The 315 further testing can be decided so that it covers the entire groups of materials of interest. Also this 316 approach takes off by identifying if there really is any exposure. The further risk assessment is based 317 on physical-chemical properties (chemical identity, physical identity, fundamental behaviour in the 318 relevant matrix, and reactivity). The authors reason that the grouping evolves by testing a few 319 selected MNMs in a group and interpolate the results to cover the entire group. As with other 320 suggested approaches, critical testing and validation of the approach is missing at this point. 321\nA different approach of grouping was taken by Simkó et al (Simkó et al., 2015). They pooled 322 published in vitro data for a set of MNMs (SiO2, TiO2, ZnO, CuO, CeO2, CNT) for two specific 323 experimental endpoints, namely ROS production as a measure for the mode of action, and cell 324 viability as a measure for toxicity. These data were then investigated for possible correlations with 325\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nparticle size, concentration, and exposure duration. Several statistically significant correlations were 326 found, based on the large available database for the metal oxide particles. No specific conclusions 327 could be made regarding CNT, due to the limited database. This is the first systematic analysis that 328 shows that pooling of data of specific endpoints, caused by MNM, into groups is useful for 329 determining specific toxic effects of at least these MNM. 330\n4.2 Material specific assessments 331\nvan Kesteren et al. (van Kesteren et al., 2015) made a risk assessment of a specific MNM, synthetic 332 amorphous silica. This material is also known as food additive E551, which is present in a number of 333 products including food, where it functions as an anticaking agent. The authors based the assessment 334 on human kinetic studies (i.e. the exposure assessment) and on in vivo toxicity studies (both oral and 335 i.v. administration studies; the hazard assessment). Importantly, this study considered sources of 336 uncertainty and recommendations for improvement. 337\nAnother publication of MNM risk assessment, with environmental focus in this case, was recently 338 published by Civardi and co-authors (Civardi et al., 2015). The study describes the case of particulate 339 (“micronized”) Cu, which contains nanosized Cu particles. The material is intended for wood 340 preservation, acting as an anti-fungal agent. However, certain strains of fungi develop Cu-resistance, 341 and the authors hypothesize that these fungi can produce Cu-loaded spores that can be inhaled by 342 humans, and possibly cause health effects. The study provides data on global annual use of the Cu-343 based particles, as well as data from relevant studies on hazard identification and characterisation. 344 On the other hand, there is no data on human or environmental exposure to Cu-based nanoparticles 345 from treated wood. The conclusion is thus that the lack of exposure data precludes a risk assessment 346 in this case. Another limitation of this study is that the authors did not consider the solubility of the 347 nano-Cu. The toxicity is likely caused by ions released from the particle and not by the Cu-MNM 348 itself. 349\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nPossible exposure to nanosized Cu was the thematic also in the studies by Platten et al (Platten et al., 350 2016) and Tegenaw et al (Tegenaw et al., 2015). The former study investigated release of Cu from Cu-351 treated lumber in order to determine possibility of dermal transfer of Cu from the wood products to 352 humans. The results showed that outdoor weathering of the lumber caused release (both ions and 353 nanoparticles) during the first two months of the one-year weathering, but not later. The study by 354 Tegenaw et al (Tegenaw et al., 2015) focused on Cu-based pesticides. Nanosized Cu-particles were 355 found in both products. Any conclusions regarding a possible environmental impact cannot be made 356 from these studies. 357\nAn exemplary environmental risk assessment (ERA) case study for a specific nano-silver (Ag-MNM, 358 NM-300K) in textiles was performed by Voelker et al (Voelker et al., 2015) . The authors applied an 359 environmental exposure assessment based on the release of Ag-MNM washed out from three 360 different types of textiles, which were used for domestic applications, into the sewer system and 361 further into the environment. The ECHA Guidance on Information Requirements and Chemical Safety 362 Assessment (ECHA, 2012) was applied for the environmental release calculations and hazard 363 assessment was performed based on existing eco-toxicological data. No environmental risk from the 364 investigated Ag-MNM was detected in this study. However, if conservative assumptions were 365 considered for surface water, the authors pointed out that by an increased emission of Ag-MNM to 366 the environment, a higher risk for sensitive aquatic organisms could appear. Thus, the introduction of 367 a threshold level controlling the release of Ag-MNM from textiles was suggested. It was also pointed 368 out that based on an inadequate database and other shortcomings, an overall RA of Ag-MNM in 369 general is not possible 370\nThere are some published studies on RA of carbon nanotubes (CNTs) in the literature. Among them, 371 Kuempel et al (Kuempel, 2011) focused on occupational RA and performed a quantitative RA based 372 on toxicity data from two sub-chronic 13-week inhalation studies of multi-walled CNT (MWCNT) in 373 rats, and on occupational exposure from four additional studies. The animal data on deposited lung 374 dose were extrapolated to humans and the obtained estimated human-equivalent concentrations 375\nM AN\nUS CR\nIP T\nAC CE\nPT ED\ngiving lowest observed adverse effect levels (LOAEL) were similar to some of the workplace 376 concentrations of airborne CNT. 377\nAnother occupational assessment was performed by Nakanishi et al (Nakanishi et al., 2015) who 378 provided occupational exposure limit (OELs) values for the CNT group of materials, including 379 MWCNT, and also single-walled (SWCNT) and double-walled (DWCNT) nanotubes. The toxicity data 380 were generated by the authors who used Wistar rats for 4-week inhalation test and instillation tests 381 and extrapolated the rat data to humans. Their exposure data were a combination of published data 382 and own measurement results from dustiness tests. The authors proposed an OEL of 0.03 mg/m3 383 which is the value of the most toxic material in the group. The authors also concluded that limiting 384 the agglomerated micrometer-scale particles is the most efficient risk management step, significantly 385 reducing the risk of workplace exposure. 386\nColl et al (Coll et al., 2016) have published an environmental RA for five nanomaterials, including 387 CNT. The RAs were quantitative risk estimates for fresh water, soils, and sediments based on 388 probabilistic Species Sensitivity Distribution (pSSD) and probabilistic predicted environmental 389 concentrations (PECs). Also here the exposure data were obtained from literature values, as well as a 390 number of eco-toxicity endpoints regarding survival, growth, reproduction, and changes in significant 391 metabolic processes for a number of environmental species. Regarding CNTs, the authors concluded 392 that these compounds do not represent any significant risk to the environment, based on that there 393 is low release of CNTs into the environment and thus a low exposure potential. 394\nA recent study from Hristozov et al. (Hristozov et al., 2014) used a quantitative weight of evidence RA 395 approach for hazard identification and analysis. This is the first time that expert evaluation of data 396 quality is applied for MNM RA according to the authors. However, the study focuses on hazard 397 identification and does not include specific exposure assessment. 398\nAnother example of occupational RA is a study by Koivisto et al. (Koivisto et al., 2014) who assessed 399 possible risks of inhalation exposure to nanodiamonds in a laboratory setting. The authors 400\nM AN\nUS CR\nIP T\nAC CE\nPT ED\ndetermined nanodiamond emission rates during handling, and performed cytotoxicity studies in the 401 human leukemia cell line THP-1. The conclusions of the study were that the exposure levels in this 402 case were low (minute fractions of the total exposure to submicrometer urban air particles) and that 403 the performed hazard assessment was insufficient for risk assessment. 404\nOther examples of occupational RA were published by Liao et al. (Liao et al., 2008) and Ling et al. 405 (Ling et al., 2011). The first of these studies focused on occupational TiO2 exposures and inhalation, 406 whereas the study from Ling and co-workers included both airborne TiO2 as well as carbon black 407 nanoparticles. The exposure assessment in the Liao study (Liao et al., 2008) was complemented with 408 experimental studies on the effects on the lungs. 409\nHristozov and co-authors (Hristozov et al., 2012) pointed to that the available RA data is limited, and 410 that especially studies on the exposure assessment part of RA are poorly characterised. Their 411 conclusion was that most available studies serve as screening tools for hazard, and that the use for 412 regulatory purposes is limited. Specific findings in the same directions were previously documented 413 by Helland et al (Helland et al., 2008). They studied 40 German and Swiss companies and reported 414 that 65% of these did not consider RA at all, whereas the remaining fraction of companies at least 415 sometimes performed some aspects of RA. A common theme among the companies was that they 416 did not foresee any unintentional release during the life cycle of the MNM in question. The authors 417 of the study also commented upon that the fate of MNM in the use and disposal stage received little 418 attention among the investigated companies. 419\n5 Specific considerations and challenges for MNM risk assessment 420\nThere are not many outcomes of MNM RA that are available in the open scientific literature. This 421 does not exclude that a substantial amount of such assessments have been performed, e.g. by 422 competent authorities but also by the industry that manufactures, uses, or disposes of MNM and 423 MNM containing products. The needs for proper RA are on the other hand stated in many 424\nM AN\nUS CR\nIP T\nAC CE\nPT ED\ndocuments (including inter alia (Borm et al., 2006; Klaine et al., 2012; Kuempel et al., 2012b; 425 Maynard et al., 2006; Savolainen et al., 2010; Schulte et al., 2016; Simkó and Mattsson, 2010; Simkó 426 and Mattsson, 2014), as well as the challenges for MNM RA, whether they are specific or not. 427\nIn general, it is considered that the currently available (eco)toxicology tests and assays are 428 appropriate also for hazard evaluation of MNM (e.g. (Kuempel et al., 2012b; Kuhnel and Nickel, 2014; 429 Oberdorster et al., 2005; OECD, 2008; OECD, 2012; Petersen et al., 2015). However, certain factors 430 may influence the toxicity of MNM relative to larger particles, or to the dissolved form of the 431 chemicals in question. A major question mark concerns exposure assessment of MNM. Furthermore, 432 due to the often complicated value chains and life cycles of MNM, knowledge about their specific 433 forms, fate and behaviour, and concentrations are difficult to obtain. Such information is absolutely 434 essential for a comprehensive RA. 435\nThis section will outline in some detail views that are expressed in various documents on the subject 436 of MNM RA, and make a summary of the challenges. 437\n5.1 The question of dose 438\nWhen performing hazard identification and hazard characterisation studies, a central question is 439 which dose(s) is/are investigated. In conventional chemical toxicology, the dose is described as the 440 administered mass of the material, which also is having a specific chemical composition. For “nano 441 toxicology” this approach has been challenged, since nanomaterial properties are largely influenced 442 by the particle size, and also by other physical-chemical characteristics of the MNM. 443\nSeveral studies have addressed the question, which is the most appropriate metric when describing 444 dose (see e.g. (Delmaar et al., 2015; Simkó et al., 2014). The latter paper proposes an MNM dose 445 model, which is analogous to the radiation protection dose model, using “deposited and equivalent 446 dose”. The authors put forward that a suitable dose metric is the deposited nanoparticle surface area 447 per tissue mass, and takes into account both primary and also agglomerated nanoparticles. 448\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nFurthermore, this work also introduces weighting factors that are based on other physical-chemical 449 properties of the MNM. These weighting factors consider the specific surface area, the surface 450 textures, the zeta-potential as a measure for surface charge, the particle morphology such as the 451 shape and the length-to-diameter ratio (aspect ratio), the band gap energy levels of metal and metal 452 oxide nanoparticles, and the particle dissolution rate. 453\nThe MNM dose question is not trivial and is a major challenge for hazard related studies of 454 nanomaterials and nanoparticles. Despite the awareness of this problem, and that some studies 455 addressing this problem have been published, systematic experimental work, which is aimed at 456 solving this problem is lacking. One study however (Mottier et al., 2016) clearly showed that surface 457 area of the used MNM is the most relevant descriptor of toxicity for different types of carbon 458 allotropes by comparing the inhibition of Xenopus laevis larvae growth after in vivo exposure to 459 different carbon nanoparticles for 12 days using different dose metrics. 460\nSome authors have also addressed methodological approaches to dose determination. Thus, DeLoid 461 et al. (DeLoid et al., 2015) developed and used two computational models (a 3-D computational fluid 462 dynamics model and a one-dimensional Distorted Grid model) to determine the actual dose of metal 463 oxide nanoparticles in cell cultures. Both models could accurately provide MNM concentration and 464 how the materials distributed in the cell culture wells over time. Petersen et al (Petersen et al., 2016) 465 overviewed a number of currently used methods for CNT quantification in different environmental 466 settings (water, soil, sediment, biological tissue). The methods were considered differently 467 appropriate, with different detection limits, needs for specific equipment and expertise, and 468 sensitivity to particle agglomeration. 469\nBy using single particle inductive coupled plasma-mass spectrometry, it is possible determine 470 nanoparticle number and size at very low concentrations (e.g. (Montano et al., 2016; Montoro Bustos 471 et al., 2015). Montoro Bustos et al (2015) further compared six laboratories that measured two gold 472 reference material nanoparticles. The inter-laboratory comparison showed a high degree of 473\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nconformity regarding particle size, but the measurement precision varied between the labs. 474 Furthermore, the comparisons also revealed that the inter-laboratory variations were different for 475 the two particles. 476\nThese examples are not addressing the most appropriate dose metric per se, but are examples of 477 how specific methodological awareness and development helps in measuring dose metrics, and thus 478 helps to deepen the understanding of appropriate metrics. 479\nAs mentioned above, for RA exposure assessment is a prerequisite. Exposure and dose are very much 480 connected to each other. A common and relevant dose definition would thus significantly improve 481 and facilitate exposure assessment. 482\n5.2 Grouping and computational approaches 483\nThe diversity of materials that have dimensions at the nanoscale is simply forbiddingly large, and is 484 expected to grow to even larger numbers. If current approaches to assess the risks of these materials 485 take place on a case-by-case-basis as is recommended by present policy papers (see e.g. (SCENIHR, 486 2009b; SCENIHR, 2009c), the assessment procedures will be too cumbersome to allow that even a 487 small fraction of the materials are appropriately assessed. Thus, approaches that streamline the work 488 are highly sought after, and will likely be the cornerstones of future assessments. However, until 489 now, these ambitions have not taken off. In general, a number of alternative and computer-based 490 approaches for toxicity testing are getting more frequently used where appropriate. These methods 491 include biokinetic modelling, SARs and QSARs. 492\nQSARs are mathematical models that are used for prediction of toxicological behaviour of chemicals 493 based on knowledge from a library of chemical structures. The assumption is that similarity in 494 chemical structure also predicts the effects in a biological system. A number of QSAR models have 495 been developed and tested both for eco-toxicology (Altenburger et al., 2003) and human toxicology 496 purposes (e.g. (Bernauer et al., 2005; Natarajan and Basak, 2011). Of special interest for 497\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nnanotoxicology is the potential to use QSARs for grouping of materials (Arts et al., 2014; Burello and 498 Worth, 2011; Nel et al., 2013; Nel et al., 2009), which is needed in a setting where novel 499 nanomaterials are constantly developed. 500\nThe potential usefulness of QSARs for toxicological testing has also been recognized by OECD and its 501 Working Party (WP) on QSARs. This WP has released a tool box for the validation of QSARs (OECD 502 2004), which was followed by further guidance at the EU-level (ECHA, 2008). Lately, it has been 503 recommended by OECD (OECD, 2012) to include methods like QSAR in the future planning of risk 504 assessment. 505\nA recent study pointed to the challenges of the nano-QSAR (Oksel et al., 2015) regarding the 506 acceptance of regulators and also of the large data needs and gaps. Also the uncertainties regarding 507 the applied models were discussed as well as the need for fully transparent methods. The authors 508 investigated 33 descriptors and 10 different metal oxide MNM and detected some strong and 509 moderate correlations between different biological endpoints and nano-characteristics. 510\n511\n5.3 Future materials 512 513 The RA efforts that have been performed so far are very likely concerned primarily with MNM that 514 belong to the so-called “first generation” nanomaterials (Roco, 2011). This category includes passive 515 nanostructures, such as metals and metal oxides, and also carbon nanotubes. There are also to some 516 extent products available that are containing active nanostructures (second generation 517 nanomaterials; functionalized MNM), such as biological and non-biological sensors, compounds for 518 medical use, and certain compounds for microelectronics. To what extent these kinds of materials 519 and products have been assessed for their possible risk to human health and the environment is 520 unknown. 521\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nThe anticipated integration of third (self-assembly and networking properties) and fourth generation 522 (molecular devices with “intelligent” properties) nanomaterials is belonging to the future. Such 523 materials are not constituents of any consumer products yet. 524\nThe risk assessment overviews that are presented in this document are primarily relevant for the 525 passive nanostructures, but are likely not appropriate for any future materials, including most of the 526 second generation MNM. It is thus prudent to be prepared for coming scenarios, especially those 527 that include the new sophisticated materials that are likely to be developed, with/without nano- 528 components. 529\nIn general it is important to understand how the physical form and chemical composition of new 530 materials interact synergistically to determine toxicology: 531\n- physical-chemical properties are important for how dose is understood 532\n- the way materials move within, interact with, and are transformed by biological systems is 533 also determined by their physical-chemical properties. 534\nNew materials will be very challenging for RA since they are likely complex multicomponent 535 materials. It is also expected that hybrid materials will be developed that blur the boundaries 536 between biological and non-biological components. Active materials that are designed to change 537 behaviour according to their environment or a received set of signals are furthermore expected. All 538 these properties, as well as many that we are unaware of presently, are likely complicating future RA 539 efforts. To what extent present day RA approaches are appropriate for future safety considerations 540 cannot be answered today, the question marks regarding materials, use, and their potential for 541 release are simply too overwhelming at this stage. 542\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n5.4 Summary of challenges 543\nThere are a number of challenges that make RA of MNM unique and possibly also to some extent 544 more complicated than RA of traditional chemicals in solution and of particles of larger size than 545 nanosized particles. Without prioritization, some of the major challenges include: 546\nManufactured nanomaterials are sophisticated materials that currently appear in many 547 forms, made up of many different chemical elements, and sometimes in combination with 548 other materials. It is likely that the development of new materials will proceed even faster, 549 leading to that the repertoire of materials needing assessment becomes forbiddingly large. 550 Thus, there is a need to find ways to perform predictive risk assessment, based on e.g. 551 grouping principles that can include a number of materials. 552 A given MNM exists along a value chain with its specific life cycle, from the initial research 553 stages to the final disposal. To what extent does the material exist at the nanoscale along 554 this chain, and to what extent are humans and/or the environment actually exposed to the 555 material? 556 A number of physical-chemical properties of MNM characterize these materials. Although 557 some knowledge has accumulated during the last years, the respective properties´ influence 558 on the toxicity of MNM needs further systematic investigation. 559 An MNM in the environment(water, soil and sediment, or air) or in an organism (including 560 the human) encounters different conditions A significant challenge deals with understanding 561 the effects of these conditions on the properties of the MNM. 562\nTable 2 expands on these considerations and give the most important challenges and corresponding 563 needs and knowledge gaps. 564\n565\n566\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n6 Discussion and Conclusions 567\nThe possible effects of MNM on human health and the environment are sometimes ascribed to the 568 „novelty“ of these materials. This could be interpreted as “novel” types of responses occur, and that 569 novel approaches for RA are needed. However, there are no data available that support such 570 assumptions. The responses in biological systems (which can be molecules, cells, tissues, or 571 organisms) to MNM are not unique, they are also appearing when chemicals in solution or larger 572 particles are interacting with biological components. Furthermore, RA of MNM requires knowledge 573 about the exposure as well as of hazard potential and dose-response relationships. This is once again 574 in line with what is required for conventional RA of chemicals. 575\nThe specific challenges for MNM risk assessment are thus of another character. Central to all RA-576 related activities is the need for profile life cycles, as depicted in Figure 4. For each stage along the 577 value chain, the properties of the MNM need to be assessed, as well as to what extent there is a real 578 exposure at that stage, and if exposure at these levels, and with an MNM in that specific form 579 actually has hazard potential. Corresponding knowledge about the effects of the pristine form of the 580 MNM is thus having very limited, if any, value for risk assessment. 581\nFor each product containing MNM, the life cycle aspect is needed in order to perform RA. This 582 framework strongly encourages the user/assessor to consider how the MNMs physical-chemical 583 properties, the hazards, and/or exposures may be altered during the materials life cycle. Basically, 584 each new stage of the value chain or life cycle offers a new setting for the RA, where the MNM in 585 question has to be treated as a unique material (changing face of MNM). 586\nThe present specific tools used in characterization of MNM, in exposure assessment, in toxicological 587 testing, and the risk assessment are appropriate, but not necessarily sufficient for RA. 588 Methodological development in material characterization and detection, especially at low levels, 589 better understanding of matrix interactions, improved understanding of tissue kinetics and effects of 590\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nlow level exposures, development of appropriate dose concepts, and development of quantitative RA 591 will help decision makers when performing MNM relevant risk management. 592\n7 Acknowledgements 593\nThis work has been partly supported by grants from the EU FP7 Programme to the projects SIINN 594 (Project #265799) and NANOREG (Project #310584). The funding agencies had no influence on any 595 part of the process leading to the writing and submission of this manuscript. 596 Parts of the content in this paper has been used in internal reports in the above mentioned projects. 597\n8 References 598\nAltenburger, R., et al., 2003. Mixture toxicity and its modeling by quantitative structure-activity 599 relationships. Environ Toxicol Chem. 22, 1900-15. 600 Arts, J. H., et al., 2015. A decision-making framework for the grouping and testing of nanomaterials 601 (DF4nanoGrouping). Regul Toxicol Pharmacol. 71, S1-27. 602 Arts, J. H. E., et al., 2014. A critical appraisal of existing concepts for the grouping of nanomaterials. 603 Regulatory Toxicology and Pharmacology. 70, 492-506. 604 Benfenati, E., et al., 2013. Using toxicological evidence from QSAR models in practice. ALTEX. 30, 19-605 40. 606 Bernauer, U., et al., 2005. The use of in vitro data in risk assessment. Basic Clin Pharmacol Toxicol. 96, 607 176-81. 608 Borm, P. J., et al., 2006. The potential risks of nanomaterials: a review carried out for ECETOC. Part 609 Fibre Toxicol. 3, 11. 610 Bos, P. M., et al., 2015. The MARINA Risk Assessment Strategy: A Flexible Strategy for Efficient 611 Information Collection and Risk Assessment of Nanomaterials. Int J Environ Res Public 612 Health. 12, 15007-21. 613 Boverhof, D. R., et al., 2015. Comparative assessment of nanomaterial definitions and safety 614 evaluation considerations. Regul Toxicol Pharmacol. 73, 137-50. 615 Braakhuis, H. M., et al., 2016. Grouping nanomaterials to predict their potential to induce pulmonary 616 inflammation. Toxicol Appl Pharmacol. 299, 3-7. 617 Burello, E., Worth, A. P., 2011. QSAR modeling of nanomaterials. Wiley Interdiscip Rev Nanomed 618 Nanobiotechnol. 3, 298-306. 619 Civardi, C., et al., 2015. Micronized copper wood preservatives: an efficiency and potential health risk 620 assessment for copper-based nanoparticles. Environ Pollut. 200, 126-32. 621 Clark, K. A., et al., 2011. Predictive models for nanotoxicology: current challenges and future 622 opportunities. Regul Toxicol Pharmacol. 59, 361-3. 623 Cohen, Y., et al., 2013. In silico analysis of nanomaterials hazard and risk. Acc Chem Res. 46, 802-12. 624 Coll, C., et al., 2016. Probabilistic environmental risk assessment of five nanomaterials (nano-TiO2, 625 nano-Ag, nano-ZnO, CNT, and fullerenes). Nanotoxicology. 10, 436-44. 626 Costa, L. G., et al., 2014. Neurotoxicants are in the air: convergence of human, animal, and in vitro 627 studies on the effects of air pollution on the brain. Biomed Res Int. 2014, 736385. 628\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nCosta, P. M., Fadeel, B., 2016. Emerging systems biology approaches in nanotoxicology: Towards a 629 mechanism-based understanding of nanomaterial hazard and risk. Toxicol Appl Pharmacol. 630 299, 101-11. 631 Dekkers, S., et al., 2016. Towards a nanospecific approach for risk assessment. Regul Toxicol 632 Pharmacol. 80, 46-59. 633 Delfino, R. J., et al., 2005. Potential role of ultrafine particles in associations between airborne 634 particle mass and cardiovascular health. Environ Health Perspect. 113, 934-46. 635 Delmaar, C. J., et al., 2015. A practical approach to determine dose metrics for nanomaterials. 636 Environ Toxicol Chem. 34, 1015-22. 637 DeLoid, G. M., et al., 2015. Advanced computational modeling for in vitro nanomaterial dosimetry. 638 Part Fibre Toxicol. 12, 32. 639 ECHA, https://echa.europa.eu/regulations/nanomaterials. Vol. 2016. 640 ECHA, Guidance on information requirements and chemical safety assessment Appendix R.7.13-2: 641 Environmental risk assessment for metals and metal compounds. European Chemicals 642 Agency, 2008, pp. 41. 643 ECHA, Guidance on information requirements and chemical safety assessment Chapter R.16: 644 Environmental Exposure Estimation Version 2.1., Vol. 2012. European Chemicals Agency, 645 Helsinki, 2012. 646 Finnveden, G., et al., 2009. Recent developments in Life Cycle Assessment. J Environ Manage. 91, 1-647 21. 648 Frampton, M. W., 2007. Does inhalation of ultrafine particles cause pulmonary vascular effects in 649 humans? Inhal Toxicol. 19 Suppl 1, 75-9. 650 Godwin, H., et al., 2015. Nanomaterial categorization for assessing risk potential to facilitate 651 regulatory decision-making. ACS Nano. 9, 3409-17. 652 Guxens, M., Sunyer, J., 2012. A review of epidemiological studies on neuropsychological effects of air 653 pollution. Swiss Med Wkly. 141, w13322. 654 Helland, A., et al., 2008. Risk assessment of engineered nanomaterials: a survey of industrial 655 approaches. Environ Sci Technol. 42, 640-6. 656 Hendren, C. O., et al., 2015. A functional assay-based strategy for nanomaterial risk forecasting. Sci 657 Total Environ. 536, 1029-37. 658 Hischier, R., Walser, T., 2012. Life cycle assessment of engineered nanomaterials: state of the art and 659 strategies to overcome existing gaps. Sci Total Environ. 425, 271-82. 660 Hristozov, D., et al., 2016. Frameworks and tools for risk assessment of manufactured nanomaterials. 661 Environ Int. 95, 36-53. 662 Hristozov, D. R., et al., 2012. Risk assessment of engineered nanomaterials: a review of available data 663 and approaches from a regulatory perspective. Nanotoxicology. 6, 880-98. 664 Hristozov, D. R., et al., 2014. A weight of evidence approach for hazard screening of engineered 665 nanomaterials. Nanotoxicology. 8, 72-87. 666 ISO/14040, Environmental management -- Life cycle assessment -- Principles and framework. 667 International Organisation for Standardisation, 2006. 668 ISO/14044, Environmental management -- Life cycle assessment -- Requirements and guidelines. . 669 International Organisation for Standardisation, 2006. 670 Klaine, S. J., et al., 2012. Paradigms to assess the environmental impact of manufactured 671 nanomaterials. Environ Toxicol Chem. 31, 3-14. 672 Koivisto, A. J., et al., 2014. Range-finding risk assessment of inhalation exposure to nanodiamonds in 673 a laboratory environment. Int J Environ Res Public Health. 11, 5382-402. 674 Kuempel, E. D., 2011. Carbon nanotube risk assessment: implications for exposure and medical 675 monitoring. J Occup Environ Med. 53, S91-7. 676 Kuempel, E. D., et al., 2012a. Development of risk-based nanomaterial groups for occupational 677 exposure control. J Nanopart Res. 14, 1029. 678 Kuempel, E. D., et al., 2012b. Risk assessment and risk management of nanomaterials in the 679 workplace: translating research to practice. Ann Occup Hyg. 56, 491-505. 680\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nKuhnel, D., Nickel, C., 2014. The OECD expert meeting on ecotoxicology and environmental fate--681 towards the development of improved OECD guidelines for the testing of nanomaterials. Sci 682 Total Environ. 472, 347-53. 683 Kumar, S., et al., 2013. Ultrafine particles in urban ambient air and their health perspectives. Rev 684 Environ Health. 28, 117-28. 685 Lazarevic, D., Finnveden, G., 2013. Life cycle aspects of nanomaterials. . KTH – Royal Insitute of 686 Technology. 687 Lewalle, P., 1999. Risk Assessment Terminology: Methodological Considerations and Provisional 688 Results. Terminology Standardization and Harmonization. . 689 Liao, C. M., et al., 2008. Model-based assessment for human inhalation exposure risk to airborne 690 nano/fine titanium dioxide particles. Sci Total Environ. 407, 165-77. 691 Ling, M. P., et al., 2011. Assessing the potential exposure risk and control for airborne titanium 692 dioxide and carbon black nanoparticles in the workplace. Environ Sci Pollut Res Int. 18, 877-693 89. 694 Liou, S. H., et al., 2015. Assessing the first wave of epidemiological studies of nanomaterial workers. J 695 Nanopart Res. 17, 413. 696 Maynard, A. D., et al., 2006. Safe handling of nanotechnology. Nature. 444, 267-9. 697 McShan, D., et al., 2014. Molecular toxicity mechanism of nanosilver. J Food Drug Anal. 22, 116-27. 698 Montano, M. D., et al., 2016. Single Particle ICP-MS: Advances toward routine analysis of 699 nanomaterials. Anal Bioanal Chem. 408, 5053-74. 700 Montoro Bustos, A. R., et al., 2015. Post hoc interlaboratory comparison of single particle ICP-MS size 701 measurements of NIST gold nanoparticle reference materials. Anal Chem. 87, 8809-17. 702 Mottier, A., et al., 2016. Surface Area of Carbon Nanoparticles: A Dose Metric for a More Realistic 703 Ecotoxicological Assessment. Nano Lett. 16, 3514-8. 704 Nakanishi, J., et al., 2015. Risk Assessment of the Carbon Nanotube Group. Risk Anal. 35, 1940-56. 705 NanoSafetyCluster, Compendium of Projects in the European NanoSafetyCluster., Vol. 2016, 706 http://www.nanosafetycluster.eu/home/european-nanosafety-cluster-compendium.html, 707 2016. 708 Natarajan, R., Basak, S. C., 2011. Numerical descriptors for the characterization of chiral compounds 709 and their applications in modeling biological and toxicological activities. Curr Top Med Chem. 710 11, 771-87. 711 Nel, A., et al., 2013. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological 712 approach and high-throughput screening. Acc Chem Res. 46, 607-21. 713 Nel, A. E., et al., 2009. Understanding biophysicochemical interactions at the nano-bio interface. Nat 714 Mater. 8, 543-57. 715 Oberdorster, G., et al., 2005. Principles for characterizing the potential human health effects from 716 exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol. 2, 8. 717 OECD, Working Party on Manufactured Nanomaterials: List of Manufactured Nanomaterials and List 718 of Endpoints for Phase One of the OECD Testing Programme. . Organisation for Economic Co-719 operation and Development, 2008. 720 OECD, Important issues on risk assessment of manufactured nanomaterials Series on the Safety of 721 Manufactured Nanomaterials, Vol. Number 33. Organisation for Economic Co-operation and 722 Development, 2012. 723 Oksel, C., et al., 2015. Structure-activity Relationship Models for Hazard Assessment and Risk 724 Management of Engineered Nanomaterials. Procedia Engineering. 102, 1500-1510. 725 Oomen, A. G., et al., 2015. Grouping and Read-Across Approaches for Risk Assessment of 726 Nanomaterials. Int J Environ Res Public Health. 12, 13415-34. 727 Oomen, A. G., et al., 2014. Concern-driven integrated approaches to nanomaterial testing and 728 assessment--report of the NanoSafety Cluster Working Group 10. Nanotoxicology. 8, 334-48. 729 Petersen, E. J., et al., 2015. Adapting OECD Aquatic Toxicity Tests for Use with Manufactured 730 Nanomaterials: Key Issues and Consensus Recommendations. Environ Sci Technol. 49, 9532-731 47. 732\nM AN\nUS CR\nIP T\nAC CE\nPT ED\nPetersen, E. J., et al., 2016. Quantification of Carbon Nanotubes in Environmental Matrices: Current 733 Capabilities, Case Studies, and Future Prospects. Environ Sci Technol. 50, 4587-605. 734 Platten, W. E., 3rd, et al., 2016. Estimating dermal transfer of copper particles from the surfaces of 735 pressure-treated lumber and implications for exposure. Sci Total Environ. 548-549, 441-9. 736 Porter, M. E., 1985. Competitive Advantage: Creating and Sustaining Superior Performance. Simon 737 and Schuster, New York. 738 Roco, M. C., 2011. The long view of nanotechnology development: the National Nanotechnology 739 Initiative at 10 years. Journal of Nanoparticle Research. 13, 427-445. 740 Savolainen, K., et al., 2010. Risk assessment of engineered nanomaterials and nanotechnologies--a 741 review. Toxicology. 269, 92-104. 742 SCENIHR, Health Effects of Exposure to EMF. 743 http://ec.europa.eu/health/archive/ph_risk/committees/04_scenihr/docs/scenihr_o_022.pd744 f, 2009a. 745 SCENIHR, 2009b. Risk Assessment of Products of Nanotechnologies. 746 SCENIHR, Scientific Committee on Emerging and Newly Identified Health Risks. Risk assessment of 747 Products of nanotechnologies. European Commission, 748 ec.europa.eu/health/ph_risk/committees/04_scenihr/docs/scenihr_o_023.pdf, 2009c, pp. 71 749 pp. 750 Schulte, P. A., et al., 2016. Taking stock of the occupational safety and health challenges of 751 nanotechnology: 2000-2015. J Nanopart Res. 18, 159. 752 Schwarze, P. E., et al., 2006. Particulate matter properties and health effects: consistency of 753 epidemiological and toxicological studies. Hum Exp Toxicol. 25, 559-79. 754 Schwirn, K., et al., 2014. Why are nanomaterials different and how can they be appropriately 755 regulated under REACH? Environmental Sciences Europe. 26, 4. 756 Sharma, M., et al., 2016. Framework to Evaluate Exposure Relevance and Data Needs for Risk 757 Assessment of Nanomaterials using in Vitro Testing Strategies. Risk Anal. 758 Simkhovich, B. Z., et al., 2008. Air pollution and cardiovascular injury epidemiology, toxicology, and 759 mechanisms. J Am Coll Cardiol. 52, 719-26. 760 Simkó, M., Mattsson, M. O., 2010. Risks from accidental exposures to engineered nanoparticles and 761 neurological health effects: a critical review. Part Fibre Toxicol. 7, 42. 762 Simkó, M., Mattsson, M. O., 2014. Interactions between nanosized materials and the brain. Curr Med 763 Chem. 21, 4200-14. 764 Simkó, M., et al., 2014. Metrics, dose, and dose concept: the need for a proper dose concept in the 765 risk assessment of nanoparticles. Int J Environ Res Public Health. 11, 4026-48. 766 Simkó, M., et al., 2015. Pooling and Analysis of Published in Vitro Data: A Proof of Concept Study for 767 the Grouping of Nanoparticles. Int J Mol Sci. 16, 26211-36. 768 Society of Toxicology, Risk Assessment: What's It All About? . Society´s Newsletter, Communiqué, 769 Special Issue, 1998, pp. 9. 770 Tegenaw, A., et al., 2015. Characterization and potential environmental implications of select Cu-771 based fungicides and bactericides employed in U.S. markets. Environ Sci Technol. 49, 1294-772 302. 773 van Kesteren, P. C., et al., 2015. Novel insights into the risk assessment of the nanomaterial synthetic 774 amorphous silica, additive E551, in food. Nanotoxicology. 9, 442-52. 775 Voelker, D., et al., 2015. Approach on environmental risk assessment of nanosilver released from 776 textiles. Environ Res. 140, 661-72. 777 Xia, T., et al., 2009. Potential health impact of nanoparticles. Annu Rev Public Health. 30, 137-50. 778 779\n780\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n9 Figure Legends 781 782\nFigure 1. Flow chart depicting the different processes that are involved in risk assessment of agents 783 for health and the environment. Importantly, there is no risk unless both exposure and hazard are 784 present. 785\nFigure 2. Schematic representation of the steps that constitute a value chain, from generation of 786 knowledge to the end-of-life. 787\nFigure 3. Generic life cycle of a MNM which is integrated into a product. 788\nFigure 4. Risk assessment of MNM requires knowledge about the hazard potential and of the actual 789 exposure, for each stage in the value chain of the given MNM-containing product. There is thus 790 possibly not appropriate to perform one single RA for a given material, but multiple ones, 791 characterising a specific stage along the value chain. 792\n793\n794\n795\n10 Tables 796 797\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n11 Figures 804 805\n806\n807\nFigure 1. 808\n809\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n810\n811\n812\n813\n814\n815\n816\n817\nFigure 2. 818\n819\n820\nM AN\nUS CR\nIP T\nED\n821\n822\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n827\n828\n829\nFigure 4. 830\n831\n832\nM AN\nUS CR\nIP T\nAC CE\nPT ED\n• Risk assessment of nanomaterials is needed for legislation and risk management • Nanomaterial risk assessment have specific challenges • These include that the materials change appearance during their lifespan • The comprehensive mapping of the material´s life cycle and exposure is vital • Thus RA for each stage in the value chain is needed/recommended"
    } ],
    "references" : [ {
      "title" : "Mixture toxicity and its modeling by quantitative structure-activity",
      "author" : [ "R Altenburger" ],
      "venue" : null,
      "citeRegEx" : "Altenburger,? \\Q2003\\E",
      "shortCiteRegEx" : "Altenburger",
      "year" : 2003
    }, {
      "title" : "A decision-making framework for the grouping and testing of nanomaterials",
      "author" : [ "Arts", "J. H" ],
      "venue" : null,
      "citeRegEx" : "Arts and H,? \\Q2015\\E",
      "shortCiteRegEx" : "Arts and H",
      "year" : 2015
    }, {
      "title" : "A critical appraisal of existing concepts for the grouping of nanomaterials",
      "author" : [ "Arts", "J.H. E" ],
      "venue" : null,
      "citeRegEx" : "Arts and E,? \\Q2014\\E",
      "shortCiteRegEx" : "Arts and E",
      "year" : 2014
    }, {
      "title" : "Using toxicological evidence from QSAR models in practice. ALTEX",
      "author" : [ "E 604 Benfenati" ],
      "venue" : null,
      "citeRegEx" : "Benfenati,? \\Q2013\\E",
      "shortCiteRegEx" : "Benfenati",
      "year" : 2013
    }, {
      "title" : "The use of in vitro data in risk assessment",
      "author" : [ "U 606 Bernauer" ],
      "venue" : "Basic Clin Pharmacol Toxicol",
      "citeRegEx" : "Bernauer,? \\Q2005\\E",
      "shortCiteRegEx" : "Bernauer",
      "year" : 2005
    }, {
      "title" : "The potential risks of nanomaterials: a review carried out for ECETOC",
      "author" : [ "608 Borm", "P. J" ],
      "venue" : null,
      "citeRegEx" : "Borm and J,? \\Q2006\\E",
      "shortCiteRegEx" : "Borm and J",
      "year" : 2006
    }, {
      "title" : "The MARINA Risk Assessment Strategy: A Flexible Strategy for Efficient",
      "author" : [ "Bos", "P. M" ],
      "venue" : null,
      "citeRegEx" : "Bos and M,? \\Q2015\\E",
      "shortCiteRegEx" : "Bos and M",
      "year" : 2015
    }, {
      "title" : "Comparative assessment of nanomaterial definitions and safety",
      "author" : [ "Boverhof", "D. R" ],
      "venue" : null,
      "citeRegEx" : "Boverhof and R,? \\Q2015\\E",
      "shortCiteRegEx" : "Boverhof and R",
      "year" : 2015
    }, {
      "title" : "Grouping nanomaterials to predict their potential to induce pulmonary",
      "author" : [ "615 Braakhuis", "H. M" ],
      "venue" : null,
      "citeRegEx" : "Braakhuis and M,? \\Q2016\\E",
      "shortCiteRegEx" : "Braakhuis and M",
      "year" : 2016
    }, {
      "title" : "QSAR modeling of nanomaterials",
      "author" : [ "E. Burello", "A.P. Worth" ],
      "venue" : "Wiley Interdiscip Rev Nanomed",
      "citeRegEx" : "Burello and Worth,? \\Q2011\\E",
      "shortCiteRegEx" : "Burello and Worth",
      "year" : 2011
    }, {
      "title" : "Micronized copper wood preservatives: an efficiency and potential health risk",
      "author" : [ "C Civardi" ],
      "venue" : null,
      "citeRegEx" : "Civardi,? \\Q2015\\E",
      "shortCiteRegEx" : "Civardi",
      "year" : 2015
    }, {
      "title" : "Predictive models for nanotoxicology: current challenges and future",
      "author" : [ "Clark", "K. A" ],
      "venue" : null,
      "citeRegEx" : "Clark and A,? \\Q2011\\E",
      "shortCiteRegEx" : "Clark and A",
      "year" : 2011
    }, {
      "title" : "In silico analysis of nanomaterials hazard and risk",
      "author" : [ "Y Cohen" ],
      "venue" : "Acc Chem Res",
      "citeRegEx" : "Cohen,? \\Q2013\\E",
      "shortCiteRegEx" : "Cohen",
      "year" : 2013
    }, {
      "title" : "Probabilistic environmental risk assessment of five nanomaterials (nano-TiO2",
      "author" : [ "C Coll" ],
      "venue" : null,
      "citeRegEx" : "Coll,? \\Q2016\\E",
      "shortCiteRegEx" : "Coll",
      "year" : 2016
    }, {
      "title" : "Neurotoxicants are in the air: convergence of human, animal, and in vitro",
      "author" : [ "Costa", "L. G" ],
      "venue" : null,
      "citeRegEx" : "Costa and G,? \\Q2014\\E",
      "shortCiteRegEx" : "Costa and G",
      "year" : 2014
    }, {
      "title" : "Emerging systems biology approaches in nanotoxicology",
      "author" : [ "P.M. Costa", "B. Fadeel" ],
      "venue" : null,
      "citeRegEx" : "Costa and Fadeel,? \\Q2016\\E",
      "shortCiteRegEx" : "Costa and Fadeel",
      "year" : 2016
    }, {
      "title" : "Towards a nanospecific approach for risk assessment",
      "author" : [ "S 631 Dekkers" ],
      "venue" : "Regul Toxicol",
      "citeRegEx" : "Dekkers,? \\Q2016\\E",
      "shortCiteRegEx" : "Dekkers",
      "year" : 2016
    }, {
      "title" : "Potential role of ultrafine particles in associations between airborne",
      "author" : [ "Delfino", "R. J" ],
      "venue" : null,
      "citeRegEx" : "Delfino and J,? \\Q2005\\E",
      "shortCiteRegEx" : "Delfino and J",
      "year" : 2005
    }, {
      "title" : "Advanced computational modeling for in vitro nanomaterial dosimetry",
      "author" : [ "DeLoid", "G. M" ],
      "venue" : null,
      "citeRegEx" : "DeLoid and M,? \\Q2015\\E",
      "shortCiteRegEx" : "DeLoid and M",
      "year" : 2015
    }, {
      "title" : "Recent developments in Life Cycle Assessment",
      "author" : [ "G 646 Finnveden" ],
      "venue" : "J Environ Manage",
      "citeRegEx" : "Finnveden,? \\Q2009\\E",
      "shortCiteRegEx" : "Finnveden",
      "year" : 2009
    }, {
      "title" : "Does inhalation of ultrafine particles cause pulmonary vascular effects",
      "author" : [ "M.W. Frampton" ],
      "venue" : null,
      "citeRegEx" : "Frampton,? \\Q2007\\E",
      "shortCiteRegEx" : "Frampton",
      "year" : 2007
    }, {
      "title" : "Nanomaterial categorization for assessing risk potential to facilitate",
      "author" : [ "H 650 Godwin" ],
      "venue" : null,
      "citeRegEx" : "Godwin,? \\Q2015\\E",
      "shortCiteRegEx" : "Godwin",
      "year" : 2015
    }, {
      "title" : "A review of epidemiological studies on neuropsychological effects of air",
      "author" : [ "M. Guxens", "J. Sunyer" ],
      "venue" : null,
      "citeRegEx" : "Guxens and Sunyer,? \\Q2012\\E",
      "shortCiteRegEx" : "Guxens and Sunyer",
      "year" : 2012
    }, {
      "title" : "Risk assessment of engineered nanomaterials: a survey",
      "author" : [ "A Helland" ],
      "venue" : null,
      "citeRegEx" : "Helland,? \\Q2008\\E",
      "shortCiteRegEx" : "Helland",
      "year" : 2008
    }, {
      "title" : "A functional assay-based strategy for nanomaterial risk forecasting",
      "author" : [ "Hendren", "C. O" ],
      "venue" : null,
      "citeRegEx" : "Hendren and O,? \\Q2015\\E",
      "shortCiteRegEx" : "Hendren and O",
      "year" : 2015
    }, {
      "title" : "Life cycle assessment of engineered nanomaterials: state of the art",
      "author" : [ "R. Hischier", "T. Walser" ],
      "venue" : null,
      "citeRegEx" : "Hischier and Walser,? \\Q2012\\E",
      "shortCiteRegEx" : "Hischier and Walser",
      "year" : 2012
    }, {
      "title" : "Frameworks and tools for risk assessment of manufactured nanomaterials",
      "author" : [ "D 660 Hristozov" ],
      "venue" : null,
      "citeRegEx" : "Hristozov,? \\Q2016\\E",
      "shortCiteRegEx" : "Hristozov",
      "year" : 2016
    }, {
      "title" : "Risk assessment of engineered nanomaterials: a review of available data",
      "author" : [ "662 Hristozov", "D. R" ],
      "venue" : null,
      "citeRegEx" : "Hristozov and R,? \\Q2012\\E",
      "shortCiteRegEx" : "Hristozov and R",
      "year" : 2012
    }, {
      "title" : "A weight of evidence approach for hazard screening",
      "author" : [ "664 Hristozov", "D. R" ],
      "venue" : null,
      "citeRegEx" : "Hristozov and R,? \\Q2014\\E",
      "shortCiteRegEx" : "Hristozov and R",
      "year" : 2014
    }, {
      "title" : "Paradigms to assess the environmental impact of manufactured",
      "author" : [ "Klaine", "S. J" ],
      "venue" : null,
      "citeRegEx" : "Klaine and J,? \\Q2012\\E",
      "shortCiteRegEx" : "Klaine and J",
      "year" : 2012
    }, {
      "title" : "Range-finding risk assessment of inhalation exposure to nanodiamonds",
      "author" : [ "Koivisto", "A. J" ],
      "venue" : null,
      "citeRegEx" : "Koivisto and J,? \\Q2014\\E",
      "shortCiteRegEx" : "Koivisto and J",
      "year" : 2014
    }, {
      "title" : "Carbon nanotube risk assessment: implications for exposure and medical",
      "author" : [ "E.D. 674 Kuempel" ],
      "venue" : null,
      "citeRegEx" : "Kuempel,? \\Q2011\\E",
      "shortCiteRegEx" : "Kuempel",
      "year" : 2011
    }, {
      "title" : "Development of risk-based nanomaterial groups for occupational",
      "author" : [ "Kuempel", "E. D" ],
      "venue" : null,
      "citeRegEx" : "Kuempel and D,? \\Q2012\\E",
      "shortCiteRegEx" : "Kuempel and D",
      "year" : 2012
    }, {
      "title" : "Risk assessment and risk management of nanomaterials",
      "author" : [ "678 Kuempel", "E. D" ],
      "venue" : null,
      "citeRegEx" : "Kuempel and D,? \\Q2012\\E",
      "shortCiteRegEx" : "Kuempel and D",
      "year" : 2012
    }, {
      "title" : "The OECD expert meeting on ecotoxicology and environmental fate-",
      "author" : [ "D. Kuhnel", "C. Nickel" ],
      "venue" : null,
      "citeRegEx" : "Kuhnel and Nickel,? \\Q2014\\E",
      "shortCiteRegEx" : "Kuhnel and Nickel",
      "year" : 2014
    }, {
      "title" : "Ultrafine particles in urban ambient air and their health perspectives",
      "author" : [ "S 683 Kumar" ],
      "venue" : null,
      "citeRegEx" : "Kumar,? \\Q2013\\E",
      "shortCiteRegEx" : "Kumar",
      "year" : 2013
    }, {
      "title" : "Life cycle aspects of nanomaterials",
      "author" : [ "D. Lazarevic", "G. Finnveden" ],
      "venue" : null,
      "citeRegEx" : "Lazarevic and Finnveden,? \\Q2013\\E",
      "shortCiteRegEx" : "Lazarevic and Finnveden",
      "year" : 2013
    }, {
      "title" : "Risk Assessment Terminology: Methodological Considerations and Provisional",
      "author" : [ "P. Lewalle" ],
      "venue" : null,
      "citeRegEx" : "Lewalle,? \\Q1999\\E",
      "shortCiteRegEx" : "Lewalle",
      "year" : 1999
    }, {
      "title" : "Model-based assessment for human inhalation exposure risk to airborne",
      "author" : [ "Liao", "C. M" ],
      "venue" : null,
      "citeRegEx" : "Liao and M,? \\Q2008\\E",
      "shortCiteRegEx" : "Liao and M",
      "year" : 2008
    }, {
      "title" : "Assessing the potential exposure risk and control for airborne titanium",
      "author" : [ "691 Ling", "M. P" ],
      "venue" : null,
      "citeRegEx" : "Ling and P,? \\Q2011\\E",
      "shortCiteRegEx" : "Ling and P",
      "year" : 2011
    }, {
      "title" : "Assessing the first wave of epidemiological studies of nanomaterial workers",
      "author" : [ "Liou", "S. H" ],
      "venue" : null,
      "citeRegEx" : "Liou and H,? \\Q2015\\E",
      "shortCiteRegEx" : "Liou and H",
      "year" : 2015
    }, {
      "title" : "Molecular toxicity mechanism of nanosilver",
      "author" : [ "D 697 McShan" ],
      "venue" : "J Food Drug Anal",
      "citeRegEx" : "McShan,? \\Q2014\\E",
      "shortCiteRegEx" : "McShan",
      "year" : 2014
    }, {
      "title" : "Single Particle ICP-MS: Advances toward routine analysis",
      "author" : [ "698 Montano", "M. D" ],
      "venue" : null,
      "citeRegEx" : "Montano and D,? \\Q2016\\E",
      "shortCiteRegEx" : "Montano and D",
      "year" : 2016
    }, {
      "title" : "Post hoc interlaboratory comparison of single particle ICP-MS size",
      "author" : [ "Montoro Bustos", "A. R" ],
      "venue" : null,
      "citeRegEx" : "Bustos and R,? \\Q2015\\E",
      "shortCiteRegEx" : "Bustos and R",
      "year" : 2015
    }, {
      "title" : "Surface Area of Carbon Nanoparticles: A Dose Metric for a More Realistic",
      "author" : [ "A 702 Mottier" ],
      "venue" : null,
      "citeRegEx" : "Mottier,? \\Q2016\\E",
      "shortCiteRegEx" : "Mottier",
      "year" : 2016
    }, {
      "title" : "Risk Assessment of the Carbon Nanotube Group",
      "author" : [ "J Nakanishi" ],
      "venue" : "Risk Anal",
      "citeRegEx" : "Nakanishi,? \\Q2015\\E",
      "shortCiteRegEx" : "Nakanishi",
      "year" : 2015
    }, {
      "title" : "Numerical descriptors for the characterization of chiral compounds",
      "author" : [ "R. Natarajan", "S.C. Basak" ],
      "venue" : null,
      "citeRegEx" : "Natarajan and Basak,? \\Q2011\\E",
      "shortCiteRegEx" : "Natarajan and Basak",
      "year" : 2011
    }, {
      "title" : "Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological",
      "author" : [ "A Nel" ],
      "venue" : null,
      "citeRegEx" : "Nel,? \\Q2013\\E",
      "shortCiteRegEx" : "Nel",
      "year" : 2013
    }, {
      "title" : "Understanding biophysicochemical interactions at the nano-bio",
      "author" : [ "Nel", "A. E" ],
      "venue" : null,
      "citeRegEx" : "Nel and E,? \\Q2009\\E",
      "shortCiteRegEx" : "Nel and E",
      "year" : 2009
    }, {
      "title" : "Principles for characterizing the potential human health effects",
      "author" : [ "G Oberdorster" ],
      "venue" : null,
      "citeRegEx" : "Oberdorster,? \\Q2005\\E",
      "shortCiteRegEx" : "Oberdorster",
      "year" : 2005
    }, {
      "title" : "Structure-activity Relationship Models for Hazard Assessment and Risk",
      "author" : [ "C Oksel" ],
      "venue" : null,
      "citeRegEx" : "Oksel,? \\Q2015\\E",
      "shortCiteRegEx" : "Oksel",
      "year" : 2015
    }, {
      "title" : "Grouping and Read-Across Approaches for Risk Assessment",
      "author" : [ "725 Oomen", "A. G" ],
      "venue" : null,
      "citeRegEx" : "Oomen and G,? \\Q2015\\E",
      "shortCiteRegEx" : "Oomen and G",
      "year" : 2015
    }, {
      "title" : "Concern-driven integrated approaches to nanomaterial testing",
      "author" : [ "727 Oomen", "A. G" ],
      "venue" : null,
      "citeRegEx" : "Oomen and G,? \\Q2014\\E",
      "shortCiteRegEx" : "Oomen and G",
      "year" : 2014
    }, {
      "title" : "Adapting OECD Aquatic Toxicity Tests for Use with Manufactured",
      "author" : [ "Petersen", "E. J" ],
      "venue" : null,
      "citeRegEx" : "Petersen and J,? \\Q2015\\E",
      "shortCiteRegEx" : "Petersen and J",
      "year" : 2015
    }, {
      "title" : "Quantification of Carbon Nanotubes in Environmental Matrices",
      "author" : [ "Petersen", "E. J" ],
      "venue" : null,
      "citeRegEx" : "Petersen and J,? \\Q2016\\E",
      "shortCiteRegEx" : "Petersen and J",
      "year" : 2016
    }, {
      "title" : "Estimating dermal transfer of copper particles from the surfaces",
      "author" : [ "W.E. Platten", "3rd" ],
      "venue" : null,
      "citeRegEx" : "Platten and 3rd,? \\Q2016\\E",
      "shortCiteRegEx" : "Platten and 3rd",
      "year" : 2016
    }, {
      "title" : "Competitive Advantage: Creating and Sustaining Superior Performance",
      "author" : [ "M.E. Porter" ],
      "venue" : null,
      "citeRegEx" : "Porter,? \\Q1985\\E",
      "shortCiteRegEx" : "Porter",
      "year" : 1985
    }, {
      "title" : "The long view of nanotechnology development: the National Nanotechnology",
      "author" : [ "M.C. 738 Roco" ],
      "venue" : null,
      "citeRegEx" : "Roco,? \\Q2011\\E",
      "shortCiteRegEx" : "Roco",
      "year" : 2011
    }, {
      "title" : "Risk assessment of engineered nanomaterials and nanotechnologies--a",
      "author" : [ "K Savolainen" ],
      "venue" : null,
      "citeRegEx" : "Savolainen,? \\Q2010\\E",
      "shortCiteRegEx" : "Savolainen",
      "year" : 2010
    }, {
      "title" : "Taking stock of the occupational safety and health challenges",
      "author" : [ "Schulte", "P. A" ],
      "venue" : null,
      "citeRegEx" : "Schulte and A,? \\Q2016\\E",
      "shortCiteRegEx" : "Schulte and A",
      "year" : 2016
    }, {
      "title" : "Particulate matter properties and health effects: consistency",
      "author" : [ "Schwarze", "P. E" ],
      "venue" : null,
      "citeRegEx" : "Schwarze and E,? \\Q2006\\E",
      "shortCiteRegEx" : "Schwarze and E",
      "year" : 2006
    }, {
      "title" : "Why are nanomaterials different and how can they be appropriately",
      "author" : [ "K Schwirn" ],
      "venue" : null,
      "citeRegEx" : "Schwirn,? \\Q2014\\E",
      "shortCiteRegEx" : "Schwirn",
      "year" : 2014
    }, {
      "title" : "Framework to Evaluate Exposure Relevance and Data Needs for Risk",
      "author" : [ "M Sharma" ],
      "venue" : null,
      "citeRegEx" : "Sharma,? \\Q2016\\E",
      "shortCiteRegEx" : "Sharma",
      "year" : 2016
    }, {
      "title" : "Air pollution and cardiovascular injury",
      "author" : [ "Simkhovich", "B. Z" ],
      "venue" : null,
      "citeRegEx" : "Simkhovich and Z,? \\Q2008\\E",
      "shortCiteRegEx" : "Simkhovich and Z",
      "year" : 2008
    }, {
      "title" : "Risks from accidental exposures to engineered nanoparticles",
      "author" : [ "M. Simkó", "M.O. Mattsson" ],
      "venue" : null,
      "citeRegEx" : "Simkó and Mattsson,? \\Q2010\\E",
      "shortCiteRegEx" : "Simkó and Mattsson",
      "year" : 2010
    }, {
      "title" : "Interactions between nanosized materials and the brain",
      "author" : [ "M. 762 Simkó", "M.O. Mattsson" ],
      "venue" : "Curr Med",
      "citeRegEx" : "Simkó and Mattsson,? \\Q2014\\E",
      "shortCiteRegEx" : "Simkó and Mattsson",
      "year" : 2014
    }, {
      "title" : "Metrics, dose, and dose concept: the need for a proper dose concept",
      "author" : [ "M 764 Simkó" ],
      "venue" : null,
      "citeRegEx" : "Simkó,? \\Q2014\\E",
      "shortCiteRegEx" : "Simkó",
      "year" : 2014
    }, {
      "title" : "Pooling and Analysis of Published in Vitro Data: A Proof of Concept Study",
      "author" : [ "M Simkó" ],
      "venue" : null,
      "citeRegEx" : "Simkó,? \\Q2015\\E",
      "shortCiteRegEx" : "Simkó",
      "year" : 2015
    }, {
      "title" : "Characterization and potential environmental implications of select Cu",
      "author" : [ "A 770 Tegenaw" ],
      "venue" : null,
      "citeRegEx" : "Tegenaw,? \\Q2015\\E",
      "shortCiteRegEx" : "Tegenaw",
      "year" : 2015
    }, {
      "title" : "Novel insights into the risk assessment of the nanomaterial",
      "author" : [ "van Kesteren", "P. C" ],
      "venue" : null,
      "citeRegEx" : "Kesteren and C,? \\Q2015\\E",
      "shortCiteRegEx" : "Kesteren and C",
      "year" : 2015
    }, {
      "title" : "Approach on environmental risk assessment of nanosilver",
      "author" : [ "D Voelker" ],
      "venue" : null,
      "citeRegEx" : "Voelker,? \\Q2015\\E",
      "shortCiteRegEx" : "Voelker",
      "year" : 2015
    }, {
      "title" : "Potential health impact of nanoparticles",
      "author" : [ "T Xia" ],
      "venue" : "Annu Rev Public Health",
      "citeRegEx" : "Xia,? \\Q2009\\E",
      "shortCiteRegEx" : "Xia",
      "year" : 2009
    } ],
    "referenceMentions" : [ {
      "referenceID" : 37,
      "context" : "Risk in the context of human and environmental toxicology is a function of hazard and exposure 99 (from IUPAC, see (Lewalle, 1999)).",
      "startOffset" : 115,
      "endOffset" : 130
    }, {
      "referenceID" : 20,
      "context" : "Regarding specific diseases, epidemiological studies have indicated a role for UFP in 137 respiratory diseases (Frampton, 2007; Kumar et al., 2013), cardiovascular disease (Delfino et al.",
      "startOffset" : 111,
      "endOffset" : 147
    }, {
      "referenceID" : 22,
      "context" : ", 2008), and also certain neurological diseases and conditions (Costa et al., 139 2014; Guxens and Sunyer, 2012).",
      "startOffset" : 63,
      "endOffset" : 112
    }, {
      "referenceID" : 25,
      "context" : "9 comprehensive framework that quantifies ecological and human health impact of a product or 177 system over its complete life cycle (Hischier and Walser, 2012).",
      "startOffset" : 133,
      "endOffset" : 160
    }, {
      "referenceID" : 36,
      "context" : "Lazarevic and Finnveden 187 identified 25 such studies (Lazarevic and Finnveden, 2013).",
      "startOffset" : 55,
      "endOffset" : 86
    }, {
      "referenceID" : 31,
      "context" : "Among them, 371 Kuempel et al (Kuempel, 2011) focused on occupational RA and performed a quantitative RA based 372 on toxicity data from two sub-chronic 13-week inhalation studies of multi-walled CNT (MWCNT) in 373 rats, and on occupational exposure from four additional studies.",
      "startOffset" : 30,
      "endOffset" : 45
    }, {
      "referenceID" : 64,
      "context" : "19 documents (including inter alia (Borm et al., 2006; Klaine et al., 2012; Kuempel et al., 2012b; 425 Maynard et al., 2006; Savolainen et al., 2010; Schulte et al., 2016; Simkó and Mattsson, 2010; Simkó 426 and Mattsson, 2014), as well as the challenges for MNM RA, whether they are specific or not.",
      "startOffset" : 35,
      "endOffset" : 227
    }, {
      "referenceID" : 57,
      "context" : "3 Future materials 512 513 The RA efforts that have been performed so far are very likely concerned primarily with MNM that 514 belong to the so-called “first generation” nanomaterials (Roco, 2011).",
      "startOffset" : 185,
      "endOffset" : 197
    } ],
    "year" : 2016,
    "abstractText" : "word count: 119 13 main text word count: 7306 14 references word count: 1844 15",
    "creator" : "Elsevier"
  }
}